Phreesia (NYSE:PHR) Hits New 12-Month High - Here's Why

Key Points

• Phreesia's stock price reached a new **52-week high** of $31.04 during trading, last reported at $30.39, with a total volume of 636,743 shares.
• Analysts have shown **positive sentiment**, with several price target increases and multiple "buy" ratings, raising the average target price to **$32.27**.
• In its latest earnings report, Phreesia reported a revenue of **$115.94 million**, beating expectations, and a **14.5% increase** compared to the same quarter last year.

Phreesia, Inc. (NYSE:PHR - Get Free Report)'s stock price hit a new 52-week high during mid-day trading on Monday . The stock traded as high as $31.04 and last traded at $30.39, with a volume of 636743 shares traded. The stock had previously closed at $29.75.

Analysts Set New Price Targets

Several research analysts recently issued reports on the company. Truist Financial raised their target price on Phreesia from $34.00 to $35.00 and gave the stock a "buy" rating in a research report on Thursday, May 29th. Citigroup reaffirmed a "buy" rating on shares of Phreesia in a research report on Wednesday, May 28th. Wall Street Zen raised shares of Phreesia from a "hold" rating to a "buy" rating in a research report on Sunday, June 1st. Canaccord Genuity Group cut their price target on shares of Phreesia from $35.00 to $34.00 and set a "buy" rating on the stock in a research report on Thursday, May 29th. Finally, KeyCorp upped their price target on shares of Phreesia from $28.00 to $35.00 and gave the company an "overweight" rating in a research report on Monday, July 14th. One research analyst has rated the stock with a Strong Buy rating and ten have assigned a Buy rating to the company. According to data from MarketBeat, the stock has an average rating of "Buy" and an average price target of $32.27.

Phreesia Stock Performance

The company has a debt-to-equity ratio of 0.02, a quick ratio of 1.95 and a current ratio of 1.95. The company has a 50 day moving average price of $27.49 and a 200 day moving average price of $26.39. The company has a market capitalization of $1.81 billion, a price-to-earnings ratio of -40.93 and a beta of 0.71.

Phreesia (NYSE:PHR - Get Free Report) last issued its earnings results on Wednesday, May 28th. The company reported ($0.07) EPS for the quarter, beating the consensus estimate of ($0.13) by $0.06. The company had revenue of $115.94 million during the quarter, compared to the consensus estimate of $115.00 million. Phreesia had a negative return on equity of 16.23% and a negative net margin of 9.83%.The firm's revenue for the quarter was up 14.5% compared to the same quarter last year. During the same period last year, the business posted ($0.05) EPS. Phreesia has set its FY 2026 guidance at EPS. Equities research analysts predict that Phreesia, Inc. will post -1.1 earnings per share for the current fiscal year.

Insider Buying and Selling at Phreesia

In other Phreesia news, Director Lisa Egbuonu-Davis sold 2,802 shares of Phreesia stock in a transaction dated Thursday, June 26th. The stock was sold at an average price of $27.67, for a total transaction of $77,531.34. Following the completion of the transaction, the director owned 22,037 shares in the company, valued at approximately $609,763.79. The trade was a 11.28% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Michael Weintraub sold 7,431 shares of Phreesia stock in a transaction dated Monday, June 9th. The shares were sold at an average price of $27.51, for a total value of $204,426.81. Following the transaction, the director owned 143,039 shares of the company's stock, valued at $3,935,002.89. This trade represents a 4.94% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 53,882 shares of company stock worth $1,513,007. 5.50% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Phreesia

A number of hedge funds have recently added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its stake in Phreesia by 2.4% during the 1st quarter. Vanguard Group Inc. now owns 4,936,515 shares of the company's stock valued at $126,177,000 after purchasing an additional 113,405 shares during the last quarter. Greenhouse Funds LLLP increased its stake in Phreesia by 12.5% in the 2nd quarter. Greenhouse Funds LLLP now owns 3,325,262 shares of the company's stock valued at $94,637,000 after buying an additional 368,352 shares during the last quarter. Champlain Investment Partners LLC lifted its position in shares of Phreesia by 20.0% during the 1st quarter. Champlain Investment Partners LLC now owns 2,946,489 shares of the company's stock worth $75,312,000 after buying an additional 490,340 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in shares of Phreesia by 108.7% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,644,988 shares of the company's stock worth $67,606,000 after buying an additional 1,377,904 shares in the last quarter. Finally, Franklin Resources Inc. lifted its position in shares of Phreesia by 0.6% during the 2nd quarter. Franklin Resources Inc. now owns 1,524,251 shares of the company's stock worth $43,380,000 after buying an additional 9,057 shares in the last quarter. Institutional investors and hedge funds own 92.10% of the company's stock.

Phreesia Company Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.